Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.98 USD | -9.26% | -8.41% | -7.59% |
Jun. 10 | BioSig Technologies Appoints Ferdinand Groenewald as Interim CFO | MT |
May. 15 | Alaunos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2022 | 2.92M | Sales 2023 | 5K | Capitalization | 16.98M |
---|---|---|---|---|---|
Net income 2022 | -37M | Net income 2023 | -35M | EV / Sales 2022 | 46.5 x |
Net cash position 2022 | 19.55M | Net cash position 2023 | 6.06M | EV / Sales 2023 | 2,184 x |
P/E ratio 2022 |
-3.74
x | P/E ratio 2023 |
-0.48
x | Employees | 1 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 85.7% |
1 day | -9.26% | ||
1 week | -8.41% | ||
Current month | -10.09% | ||
1 month | -20.97% | ||
3 months | -40.61% | ||
6 months | +46.16% | ||
Current year | -7.59% |
Managers | Title | Age | Since |
---|---|---|---|
Dale Hogue
CEO | Chief Executive Officer | 54 | Dec. 28 |
Director of Finance/CFO | 62 | 21-02-16 | |
Melinda Lackey
ADM | Chief Administrative Officer | 47 | 21-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jaime Vieser
BRD | Director/Board Member | 54 | 20-12-15 |
Holger Weis
CHM | Chairman | 61 | 20-12-15 |
Robert Postma
BRD | Director/Board Member | 70 | 21-02-04 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 0 M€ | 0.00% | - | |
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-12 | 0.98 | -9.26% | 36,263 |
24-06-11 | 1.08 | +3.85% | 7,479 |
24-06-10 | 1.04 | +4.00% | 11,894 |
24-06-07 | 1 | -2.91% | 54,185 |
24-06-06 | 1.03 | -3.74% | 17,100 |
Delayed Quote Nasdaq, June 12, 2024 at 04:00 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-7.59% | 17.29M | |
+16.93% | 124B | |
+17.01% | 109B | |
-7.23% | 23.84B | |
+1.98% | 22.42B | |
-14.29% | 17.5B | |
-6.79% | 16.61B | |
-37.63% | 16.43B | |
+2.17% | 13.4B | |
+24.42% | 11.47B |
- Stock Market
- Equities
- TCRT Stock